Literature DB >> 20951921

The gastrointestinal complications of oncologic therapy.

Mehnaz A Shafi1, Robert S Bresalier.   

Abstract

A spectrum of oncologic treatments including chemotherapy, radiotherapy, and molecular targeted therapies is available to combat cancer. These treatments are associated with adverse effects in several organ systems including the gastrointestinal (GI) tract. The immunocompromised state induced by oncologic therapy is also an important contributing factor underlying GI complications. This review discusses common GI complications that can result from cancer therapy. The pathologic mechanisms underlying each complication and the pharmacology of the agents used to treat these complications are discussed.
Copyright © 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20951921     DOI: 10.1016/j.gtc.2010.08.004

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  9 in total

1.  Survivors of childhood cancer have increased risk of gastrointestinal complications later in life.

Authors:  Robert Goldsby; Yan Chen; Shannon Raber; Linda Li; Karen Diefenbach; Margarett Shnorhavorian; Nina Kadan-Lottick; Fay Kastrinos; Yutaka Yasui; Marilyn Stovall; Kevin Oeffinger; Charles Sklar; Gregory T Armstrong; Leslie L Robison; Lisa Diller
Journal:  Gastroenterology       Date:  2011-03-17       Impact factor: 22.682

2.  Patient-reported symptoms and quality of life integrated into clinical cancer care.

Authors:  Donna L Berry
Journal:  Semin Oncol Nurs       Date:  2011-08       Impact factor: 2.315

3.  Intestinal Obstruction in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.

Authors:  Arin L Madenci; Stacey Fisher; Lisa R Diller; Robert E Goldsby; Wendy M Leisenring; Kevin C Oeffinger; Leslie L Robison; Charles A Sklar; Marilyn Stovall; Rita E Weathers; Gregory T Armstrong; Yutaka Yasui; Christopher B Weldon
Journal:  J Clin Oncol       Date:  2015-08-10       Impact factor: 44.544

4.  The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation.

Authors:  Håkon Reikvam; Kimberley Hatfield; Øystein Bruserud
Journal:  Metabolomics       Date:  2015-11-16       Impact factor: 4.290

Review 5.  Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments.

Authors:  Rachel M McQuade; Vanesa Stojanovska; Raquel Abalo; Joel C Bornstein; Kulmira Nurgali
Journal:  Front Pharmacol       Date:  2016-11-03       Impact factor: 5.810

Review 6.  Ilececum: A Comprehensive Review.

Authors:  Shou-Jiang Tang; Ruonan Wu
Journal:  Can J Gastroenterol Hepatol       Date:  2019-02-03

7.  BCc1, the novel antineoplastic nanocomplex, showed potent anticancer effects in vitro and in vivo.

Authors:  Somayeh Kalanaky; Maryam Hafizi; Saideh Fakharzadeh; Mohammad Vasei; Ladan Langroudi; Ehsan Janzamin; Seyed Mahmoud Hashemi; Maryam Khayamzadeh; Masoud Soleimani; Mohammad Esmaeil Akbari; Mohammad Hassan Nazaran
Journal:  Drug Des Devel Ther       Date:  2015-12-30       Impact factor: 4.162

8.  Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model.

Authors:  Xiao-Hua Zhang; En-Qi Qiao; Zhenzhen Gao; Hua-Qing Yuan; Pei-Fen Cai; Xiao-Min Li; Yan-Hong Gu
Journal:  Oncol Lett       Date:  2013-05-14       Impact factor: 2.967

Review 9.  Palifermin for the protection and regeneration of epithelial tissues following injury: new findings in basic research and pre-clinical models.

Authors:  Paul W Finch; Lawrence J Mark Cross; Daniel F McAuley; Catherine L Farrell
Journal:  J Cell Mol Med       Date:  2013-09       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.